Elena A. Ulrikh

Dr. Elena A. Ulrikh


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
MOMaaike H.M. Oonk
Maaike H.M. Oonk
FPFrançois Planchamp
François Planchamp
PBPeter Baldwin
Peter Baldwin
SMSven Mahner
Sven Mahner
MMMansoor Raza Mirza
Mansoor Raza Mirza
Ignacio ZapardielIgnacio Zapardiel
Ignacio Zapardiel
Background As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynaecological Oncology (ESGO) first published in 2017 evidence-based guidelines for the management of patients with vulvar cancer. Objective To update the ESGO guidelines based on the new evidence addressing the management of vulvar cancer and to cover new topics in order to provide comprehensive guidelines on all relevant issues of diagnosis and treatment of vulvar cancer. Methods The ESGO Council nominated an international development group comprised of practicing clinicians who provide care to vulvar cancer patients and have demonstrated leadership through their expertize in clinical care and research, national and international engagement and profile as well as dedication to the topics addressed to serve on the expert panel (18 experts across Europe). To ensure that the statements were evidence-based, new data identified from a systematic search were reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Prior to publication, the guidelines were reviewed by 206 international practitioners in cancer care delivery and patient representatives. Results The updated guidelines cover comprehensively diagnosis and referral, staging, pathology, pre-operative investigations, surgical management (local treatment, groin treatment, sentinel lymph node procedure, reconstructive surgery), (chemo)radiotherapy, systemic treatment, treatment of recurrent disease (vulvar, inguinal, pelvic, and distant recurrences), and follow-up. Management algorithms are also defined.

1 May 2017 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
MOMaaike H.M. Oonk
Maaike H.M. Oonk
FPFrancois Planchamp
Francois Planchamp
PBPeter Baldwin
Peter Baldwin
MBMariusz Bidziński
Mariusz Bidziński
MBMats Brännström
Mats Brännström
AZAte G.J. van der Zee
Ate G.J. van der Zee

27 August 2021 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
GSGloria Salvo
Gloria Salvo
PRPedro T. Ramirez
Pedro T. Ramirez
MLMario M. Leitao
Mario M. Leitao
DCDavid Cibula
David Cibula
XWXiaohua Wu
Xiaohua Wu
RPRene Pareja
Rene Pareja

1 March 2019 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
GSGloria Salvo
Gloria Salvo
PRPedro T Ramirez
Pedro T Ramirez
MLMario Leitao
Mario Leitao
DCDavid Cibula
David Cibula
CFChristina Fotopoulou
Christina Fotopoulou
RPRene Pareja
Rene Pareja
Background Radical trachelectomy is considered a viable option for fertility preservation in patients with low-risk, early-stage cervical cancer. Standard approaches include laparotomy or minimally invasive surgery when performing radical trachelectomy. Primary Objective To compare disease-free survival between patients with FIGO (2009) stage IA2 or IB1 (≤2cm) cervical cancer who underwent open versus minimally invasive (laparoscopic or robotic) radical trachelectomy. Study Hypothesis We hypothesize that minimally invasive radical trachelectomy has similar oncologic outcomes to those of the open approach. Study Design This is a collaborative, multi-institutional, international, retrospective study. Patients who underwent a radical trachelectomy and lymphadenectomy between January 1, 2005 and December 31, 2017 will be included. Institutional review board approval will be required. Each institution will be provided access to a study-specific REDCap (Research Electronic Data Capture) database maintained by MD Anderson Cancer Center and will be responsible for entering patient data. Inclusion Criteria Patients with squamous, adenocarcinoma, or adenosquamous cervical cancer FIGO (2009) stages IA2 and IB1 (≤2 cm) will be included. Surgery performed by the open approach or minimally invasive approach (laparoscopy or robotics). Tumor size ≤2 cm, by physical examination, ultrasound, MRI, CT, or positron emission tomography (at least one should confirm a tumor size ≤2 cm). Centers must contribute at least 15 cases of radical trachelectomy (open, minimally invasive, or both). Exclusion Criteria Prior neoadjuvant chemotherapy or radiotherapy to the pelvis for cervical cancer at any time, prior lymphadenectomy, or pelvic retroperitoneal surgery, pregnant patients, aborted trachelectomy (intra-operative conversion to radical hysterectomy), or vaginal approach. Primary Endpoint The primary endpoint is disease-free survival measured as the time from surgery until recurrence or death due to disease. To evaluate the primary objective, we will compare disease-free survival among patients with FIGO (2009) stage IA2 or IB1 (≤2cm) cervical cancer who underwent open versus minimally invasive radical trachelectomy. Sample Size An estimated 535 patients will be included; 256 open and 279 minimally invasive radical trachelectomy. Previous studies have shown that recurrence rates in the open group range from 3.8% to 7.6%. Assuming that the 4.5-year disease-free survival rate for patients who underwent open surgery is 95.0%, we have 80% power to detect a 0.44 HR using α level 0.10. This corresponds to an 89.0% disease-free survival rate at 4.5 years in the minimally invasive group.

9 September 2014 in Gynecological Endocrinology
Verified
Journal Article
Closed access
ZGZaynab Gamzatova
Zaynab Gamzatova
EKEduard Komlichenko
Eduard Komlichenko
AKAnna Kostareva
Anna Kostareva
MGMichael Galagudza
Michael Galagudza
EUElena A. Ulrikh
Elena A. Ulrikh
EKEvgenia Kalinina
Evgenia Kalinina
To review the literature and to present the latest advances in the autotransplantation of cryopreserved ovarian tissue. A literature review was conducted for all relevant articles assessing the fertility preservation, ovarian tissue transplantation, standard freezing and vitrification of ovarian tissue. One of the promising and effective methods for fertility preservation may be the autotransplantation of cryopreserved ovarian tissue. At present, 30 babies have been born after orthotopic autotransplantation of frozen-thawed human ovarian tissue. Restoration of ovarian activity occurs between 3.5 months and 6.5 months. The longevity of autotransplanted ovarian tissue is about 5-7 years. The follicles are similarly preserved after all freezing methods; however, the ovarian stroma is significantly better preserved after vitrification than after slow freezing. An important topic for further research is preparation of the "vascular bed", optimization of vitrification technique and the development of alternative procedures to avoid the transmission of cancer cells via ovarian tissue autotransplantation - "artificial ovary". Cryopreservation of ovarian tissue has unique advantages over other strategies. This method: (1) does not delay cancer treatment; (2) is safer for hormone dependent malignancy; (3) can be done independent of menstrual cycles; (4) is the only option for prepubertal girls; (5) can restore not only fertility but endocrine function.

1 November 2011 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
MGMurat Gultekin
Murat Gultekin
PDPolat Dursun
Polat Dursun
BVBoris Vranes
Boris Vranes
RLRene Laky
Rene Laky
MBMichaela Bossart
Michaela Bossart
VSVladyslav Sukhin
Vladyslav Sukhin